News and Announcements
Phylogica Limited (ASX: PYC) set to reach experimental milestone
- Published July 19, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Phylogica Limited (ASX: PYC) is expected to complete their experience of delivering Cre Cargo into the nucleus cells in multiple tissues in live animals.
- The success of the delivery will represent a significant milestone for the company, transitioning them from proof of concept to therapeutic cargoes.
Phylogica (ASX: PYC) has announced that their experimental timelines are on track. The company will deliver the Cre cargo (enzyme) into the nucleus cells in multiple tissues in a live animal in July 2018. Phylogica’s core asset is their structurally diverse drug library which the company has chosen to use in identifying Cell Penetrating Peptides (CPPs). The successful delivery of the Cre cargo in the animal experiments will be a significant milestone for the company and help with the commercial validation of the company’s biological peptides. It will enable the transition for proof of concept stage of validating their platform to the testing of therapeutic drug cargoes.
The company has an opportunity to improve their attractiveness of the platform by delivering a cargo class of interest into a target cell more efficiently than competitive technology. The company’s original CPP has already successfully delivered Cre into kidney cells. The company has also commenced further screening of their re-populated libraries to identify additional CPPs and has gained strong interest from biotech companies who are looking for effective delivery platforms for their developed drug cargoes.
About Phylogica Limited (ASX: PYC)
Phylogica’s drug delivery platform harnesses the power of viruses and bacteria for good. These organisms have long been known to cross the cell wall to where the highest value drug targets reside. Phylogica’s delivery technology uses their genetic secrets to take drug cargoes where they cannot go alone – unlocking the undruggable genome.
Company Updates
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
